Stocks and Investing
Stocks and Investing
Mon, April 22, 2013
[ 06:45 AM ] - United States, WOPRAI
[ 05:00 AM ] - United States, Market Wire
[ 04:18 AM ] - United States, Market Wire
[ 04:00 AM ] - United States, Market Wire
[ 03:30 AM ] - United States, Market Wire
[ 03:00 AM ] - United States, Market Wire
[ 02:47 AM ] - United States, WOPRAI
[ 02:47 AM ] - United States, WOPRAI
[ 02:46 AM ] - United States, WOPRAI
[ 02:46 AM ] - United States, WOPRAI
[ 02:46 AM ] - United States, WOPRAI
[ 02:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $91 on, Apr 22nd, 2013
Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $45 to $91 on, Apr 22nd, 2013.
Matthew has made no other calls on VRTX in the last 4 months.
There is 1 other peer that has a rating on VRTX. Out of the 1 peers that are also analyzing VRTX, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Debjit Chattopadhyay of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $54 on, Wednesday, January 2nd, 2013
Contributing Sources